Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - biresp
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp581794a330b2afc7f7af3badc000c4a2
identifier: http://ema.europa.eu/identifier
/EU/1/14/921/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: BiResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-581794a330b2afc7f7af3badc000c4a2
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/14/921/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - biresp
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
BiResp Spiromax contains two different active substances: budesonide and formoterol fumarate dihydrate.
BiResp Spiromax is indicated for use in adults and adolescents 12 years of age and older only.
Your doctor has prescribed this medicine to treat asthma or chronic obstructive pulmonary disease (COPD).
Asthma BiResp Spiromax can be prescribed for asthma in two different ways.
a) You may be prescribed two asthma inhalers: BiResp Spiromax together with a separate reliever inhaler such as salbutamol.
b) You may be prescribed BiResp Spiromax as your only asthma inhaler.
Chronic obstructive pulmonary disease (COPD) COPD is a long-term lung disease of the airways in the lungs, which is often caused by cigarette smoking.
Symptoms include shortness of breath, cough, chest discomfort and coughing up mucus. BiResp Spiromax can also be used to treat the symptoms of severe COPD in adults only.
Do not use BiResp Spiromax if You are allergic to budesonide, formoterol fumarate dihydrate, or the other ingredient in this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor,pharmacist or nurse before taking BiResp Spiromax if
If you have been taking steroid tablets for your asthma or COPD, your doctor may reduce the number of tablets that you take, once you start to use BiResp Spiromax. If you have been taking steroid tablets for a long time, your doctor may want you to have regular blood tests. When reducing steroid tablets, you may feel generally unwell even though your chest symptoms may be improving. You might experience symptoms such as a stuffy or runny nose, weakness or joint or muscle pain and rash (eczema). If any of these symptoms bother you, or if symptoms such as headache, tiredness, nausea (feeling sick) or vomiting (being sick) occur, please contact your doctor immediately. You may need to take other medicines if you develop allergic or arthritic symptoms. You should speak to your doctor if you are concerned as to whether you should continue to use BiResp Spiromax.
Your doctor may consider adding steroid tablets to your usual treatment if you have an illness such as a chest infection or before an operation.
Contact your doctor if you experience blurred vision or other visual disturbances.
Children Do not give this medicine to children under the age of 12 years.
Other medicines and BiResp Spiromax Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
Some medicines may increase the effects of BiResp Spiromax and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat).
If any of the above applies to you, or if you are not sure, talk to your doctor, pharmacist or nurse before using BiResp Spiromax.
Also tell your doctor, pharmacist or nurse if you are going to have a general anaesthetic for an operation or for dental work to help lower any risk of interaction with the anesthetic you receive.
Pregnancy and breast-feeding
Driving and using machines BiResp Spiromax is not likely to affect your ability to drive or to use tools or machines.
BiResp Spiromax contains lactose
Lactose is a type of sugar found in milk. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before using this medicine.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.
Asthma
BiResp Spiromax can be prescribed for asthma in two different ways. The amount of BiResp Spiromax to use and when to use it depends on how it has been prescribed for you.
(A) Using BiResp Spiromax and a separate reliever inhaler
Use your BiResp Spiromax every day. This helps to prevent asthma symptoms from occurring.
Recommended dose:
Adults (18 years and older) 1 or 2 inhalations (actuations), twice a day, taken in the morning and in the evening.
Your doctor may increase this to 4 inhalations, twice a day. If your symptoms are well controlled, your doctor may ask you to take your medicine once a day.
Adolescents (12 years and older) 1 or 2 inhalations twice daily.
Your doctor will help you to manage your asthma and will adjust the dose of this medicine to the lowest dose that controls your asthma. If your doctor feels that you need a lower dose than is available from your BiResp Spiromax, your doctor may prescribe an alternative inhaler containing the same active substances as your BiResp Spiromax but with a lower dose of the corticosteroid. If your symptoms are well controlled, your doctor may ask you to take your medicine once a day. However, do not adjust the number of inhalations your doctor has prescribed without talking to your doctor first.
Use your separate reliever inhaler to treat asthma symptoms when they happen.
Always keep your reliever inhaler with you and use it to relieve sudden attacks of breathlessness and wheezing. Do not use BiResp Spiromax to treat these asthma symptoms.
(B) Using BiResp Spiromax as your only asthma inhaler
Only use BiResp Spiromax in this way if your doctor has told you to.
Use your BiResp Spiromax every day. This helps to prevent asthma symptoms from occurring.
Recommended dose
Adults and adolescents (12 years and older)
1 inhalation in the morning and 1 inhalation in the evening or 2 inhalations in the morning
or 2 inhalations in the evening.
Your doctor may increase this to 2 inhalations twice a day.
Also use BiResp Spiromax as a reliever inhaler to treat asthma symptoms when they happen and to prevent asthma symptoms from happening (for example, when exercising or on exposure to allergens).
Always keep your BiResp Spiromax with you and use it to relieve sudden attacks of breathlessness and wheezing.
A total daily dose of more than 8 inhalations is not normally needed. However, your doctor may allow you to take up to 12 inhalations a day for a limited period.
If you regularly need to use 8 or more inhalations a day, make an appointment to see your doctor. They may need to change your treatment.
Do NOT use more than 12 inhalations in total in 24 hours.
If you are doing exercise and you get asthma symptoms, use BiResp Spiromax as described here. However, do not use BiResp Spiromax just before exercise to stop asthma symptoms from happening.
It is important that you discuss with your doctor the use of BiResp Spiromax to prevent asthma symptoms from happening; how often you exercise or how often you are exposed to allergens could impact the treatment that is prescribed to you.
Chronic Obstructive Pulmonary Disease (COPD)
Recommended dose: Adults (18 years and older) only: 2 inhalations twice a day, taken in the morning and in the evening
Your doctor may also prescribe another bronchodilator medicine, for example an anticholinergic (such as tiotropium or ipratropium bromide) for your COPD disease.
Preparing your new BiResp Spiromax
Before using your new BiResp Spiromax for the first time, you need to prepare it for use as follows: Open the foil pouch by tearing at the notch at the top of the foil pouch and take out the inhaler Check the dose indicator to see that there are 120 inhalations in the inhaler. Write the date you opened the foil pouch on the label of the inhaler. Do not shake your inhaler before use.
How to take an inhalation Every time you need to take an inhalation, follow the instructions below.
Hold your inhaler with the semi-transparent wine red mouthpiece cover at the bottom.
Open the mouthpiece cover by folding it down until one loud click is heard. Your medicine is actively metered. Your inhaler is now ready for use.
Breathe out gently (as far as is comfortable). Do not breathe out through your inhaler.
Place the mouthpiece between your teeth. Do not bite the mouthpiece. Close your lips around the mouthpiece. Take care not to block the air vents.
Breathe in through your mouth as deeply and as hard as you can.
If you are to take a second inhalation, repeat steps 1 to 7. Rinse your mouth with water after every dose, and spit it out.
Do not try to take your inhaler apart, remove or twist the mouthpiece cover, it is fixed to your inhaler and must not be taken off. Do not use your Spiromax if it has been damaged or if the mouthpiece has come apart from your Spiromax. Do not open and close the mouthpiece cover unless you are about to use your inhaler.
Cleaning your Spiromax Keep your Spiromax dry and clean. If necessary, you may wipe the mouthpiece of your Spiromax after use with a dry cloth or tissue.
When to start using a new Spiromax
The dose indicator tells you how many doses (inhalations) are left in your inhaler, starting with inhalations when it is full and ending with 0 (zero) inhalations when it is empty.
The dose indicator, on the rear of the device, shows the number of inhalations remaining as even numbers. The spaces between the even numbers represent the odd number of remaining inhalations..
For inhalations remaining from 20 downwards to 8 , 6 , 4 , 2 the numbers are displayed in red on a white background. When the numbers become red in the window, you should consult your doctor and obtain a new inhaler.
Note:
Important information about your asthma or COPD symptoms
If you feel you are getting breathless or wheezy while using BiResp Spiromax, you should continue to use BiResp Spiromax but go to see your doctor as soon as possible, as you may need additional treatment.
Contact your doctor immediately if:
These signs could mean that your asthma or COPD is not being properly controlled and you may need different or additional treatment immediately.
Once your asthma is well controlled your doctor may consider it appropriate to gradually reduce the dose of BiResp Spiromax.
If you use more BiResp Spiromax than you should It is important that you take your dose as advised by your doctor. You should not exceed your prescribed dose without seeking medical advice.
If you use more BiResp Spiromax than you should, contact your doctor, pharmacist or nurse for advice. The most common symptoms that may occur after when you use more BiResp Spiromax than you should are trembling, headache or a rapid heartbeat.
If you forget to use BiResp Spiromax If you forget to take a dose, take it as soon as you remember. However do not take a double dose to make up for a forgotten dose. If it is nearly time for your next dose just take your next dose at the usual time.
If you become wheezy or breathless, or develop any other symptoms of an asthma attack, use your reliever inhaler , then seek medical advice.
If you stop using BiResp Spiromax Do not stop using your inhaler without telling your doctor first.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If any of the following happen to you, stop using BiResp Spiromax and talk to your doctor immediately:
Rare side effects: may affect up to 1 in 1,000 people
Very rare side effects: may affect up to 1 in 10,000 people
Other possible side effects:
Common: may affect up to 1 in 10 people
Tell your doctor if you have any of the following while taking BiResp Spiromax they could be symptoms of a lung infection:
Uncommon: may affect up to 1 in 100 people
Rare:
Very rare:
These effects happen very rarely and are much less likely to happen with inhaled corticosteroids than with corticosteroid tablets.
Reporting of side effects If you get any side effects, talk to your doctor,pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
What BiResp Spiromax contains
What BiResp Spiromax looks like and contents of the pack BiResp Spiromax is an inhalation powder.
Each BiResp Spiromax inhaler contains 120 inhalations and has a white body with a semi-transparent wine red mouthpiece cover.
Packs of 1, 2, and 3 inhalers. Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder
Teva Pharma B.V.,
Swensweg 5, 2031GA Haarlem, The Netherlands.
Manufacturer
Norton (Waterford) Limited Unit 27/35, IDA Industrial Park, Cork Road, Waterford, Ireland
Teva Pharmaceuticals Europe B.V., Swensweg 5, 2031 GA Haarlem, Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG
Tel/T l: +32 3 820 73 Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG
Belgique/Belgien
Tel/T l: +32 3 820 73
Te : +359 2 489 95 Magyarorsz g Teva Gy gyszergy r Zrt.
Tel.: +36 1 288 64 esk republika Teva Pharmaceuticals CR, s.r.o.
Tel: +420 251 007 Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 207 540 7Danmark Teva Denmark A/S
Tlf: +45 44 98 55 Nederland Teva Nederland B.V. Tel: +31 800 0228 Deutschland Teva GmbH Tel: +49 731 402 Norge Teva Norway AS
Tlf: +47 6677 55 Eesti UAB Teva Baltics Eesti filiaal Tel: +372 661 0 sterreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007 0
Teva . . : +30 210 880 5Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel.: +48 22 345 93 Espa a Laboratorios BIAL, S.A. Tel.: +34 915624Portugal
Teva Pharma - Produtos Farmac uticos, Lda. Tel: +351 21 476 75 France Teva Sant
T l: +33 1 55 91 7Rom nia Teva Pharmaceuticals S.R.L Tel: +4021 230 6Ireland Teva Pharmaceuticals Ireland Tel: +44 207 540 7Slovenija Pliva Ljubljana d.o.o. Tel: +386 1 58 90 sland Alvogen ehf. S mi: + 354 522 2Slovensk republika Teva Pharmaceuticals Slovakia s.r.o. Tel: +421 2 5726 7Italia Teva Italia S.r.l. Tel: +39 028 917 Suomi/Finland Teva Finland Oy Puh/Tel: +358 20 180 5
Specifar A.B.E.E.
: +30 211 880 5Sverige Teva Sweden AB Tel: +46 42 12 11 Latvija UAB Teva Baltics fili le Latvij
Tel: +371 67 323 United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 207 540 7Lietuva UAB Teva Baltics Tel: +370 5 266 02 Hrvatska Pliva Hrvatska d.o.o. Tel: + 385 1 37 20 This leaflet was last revised in month YYYY.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-581794a330b2afc7f7af3badc000c4a2
Resource Composition:
Generated Narrative: Composition composition-en-581794a330b2afc7f7af3badc000c4a2
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/14/921/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - biresp
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp581794a330b2afc7f7af3badc000c4a2
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp581794a330b2afc7f7af3badc000c4a2
identifier:
http://ema.europa.eu/identifier
/EU/1/14/921/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: BiResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en